BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 21, 2005
View Archived Issues
Positive preclinical results for HIV protease inhibitor PPL-100
Read More
NTR1: an RVM target for antinociception
Read More
Follistatin improves pulmonary fibrosis in rats
Read More
ALGRX-4975 induces significant pain relief in patients with Morton's neuroma
Read More
Virulizin phase III study results announced
Read More
Positive in vitro results for bactericidal antibiotic AR-709
Read More
Submission for Zimycan deemed a complete response
Read More
Phase II trial begins for Elacyt in malignant melanoma
Read More
Galapagos acquires BioFocus
Read More
Companies gear up efforts for possible flu pandemic
Read More
Dosing begins in phase I study of rFXIII in cardiac surgery patients
Read More
Phase I study begins for SEP-225289 for major depressive disorder
Read More
Phase III clevidipine safety trials to resume
Read More
Financing to support continuation of phase III clinical benefit study of Riquent
Read More
Next-generation cephalosporin PPI-0903 begins phase II study
Read More
ADT trial of Acapodene reaches target enrollment
Read More
Study to investigate if comprehensive antiplatelet therapy prevents heart damage
Read More
Biopure updates status of Hemopure development program
Read More
Polypill therapy may result promising for NAFLD
Read More
ProK-60: a new antiaging product
Read More
Snapshots on new products in the treatment of MS
Read More
Preliminary phase II data on the safety of erlotinib plus bevacizumab in kidney cancer
Read More
Good safety and pharmacokinetic profile of tolvaptan in CHF patients
Read More
Recent patents cover novel treatments for psychiatric disorders
Read More
Prostanoid EP2 receptor agonists for gynecological disorders claimed in recent Pharmagene patent
Read More